DKK 1120.0
(-2.61%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - DKK | 0.0% |
2022 | - DKK | -100.0% |
2021 | 36.19 Million DKK | 0.0% |
2020 | - DKK | 0.0% |
2019 | - DKK | 0.0% |
2018 | - DKK | 0.0% |
2017 | - DKK | 0.0% |
2016 | - DKK | 0.0% |
2015 | - DKK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - DKK | 0.0% |
2024 Q2 | - DKK | 0.0% |
2023 Q4 | - DKK | 0.0% |
2023 Q3 | - DKK | 0.0% |
2023 Q1 | - DKK | 0.0% |
2023 Q2 | - DKK | 0.0% |
2023 FY | - DKK | 0.0% |
2022 Q1 | - DKK | -100.0% |
2022 Q4 | - DKK | 0.0% |
2022 FY | - DKK | -100.0% |
2022 Q2 | - DKK | 0.0% |
2021 Q1 | - DKK | 0.0% |
2021 FY | 36.19 Million DKK | 0.0% |
2021 Q3 | - DKK | -100.0% |
2021 Q4 | 23.04 Million DKK | 0.0% |
2021 Q2 | 13.15 Million DKK | 0.0% |
2020 Q1 | - DKK | 0.0% |
2020 FY | - DKK | 0.0% |
2020 Q4 | - DKK | 0.0% |
2020 Q3 | - DKK | 0.0% |
2020 Q2 | - DKK | 0.0% |
2019 Q1 | - DKK | 0.0% |
2019 Q3 | - DKK | 0.0% |
2019 Q2 | - DKK | 0.0% |
2019 Q4 | - DKK | 0.0% |
2019 FY | - DKK | 0.0% |
2018 Q3 | - DKK | 0.0% |
2018 Q4 | - DKK | 0.0% |
2018 Q2 | - DKK | 0.0% |
2018 FY | - DKK | 0.0% |
2018 Q1 | - DKK | 0.0% |
2017 Q2 | - DKK | 0.0% |
2017 Q3 | - DKK | 0.0% |
2017 Q4 | - DKK | 0.0% |
2017 FY | - DKK | 0.0% |
2017 Q1 | - DKK | 0.0% |
2016 Q4 | - DKK | 0.0% |
2016 FY | - DKK | 0.0% |
2016 Q2 | - DKK | 0.0% |
2016 Q1 | - DKK | 0.0% |
2016 Q3 | - DKK | 0.0% |
2015 FY | - DKK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
ALK-Abelló A/S | 4.82 Billion DKK | 100.0% |
Bavarian Nordic A/S | 7.05 Billion DKK | 100.0% |
Genmab A/S | 16.47 Billion DKK | 100.0% |
Gubra A/S | 205 Million DKK | 100.0% |
Novo Nordisk A/S | 232.26 Billion DKK | 100.0% |
Pharma Equity Group A/S | - DKK | NaN% |
Zealand Pharma A/S | 342.78 Million DKK | 100.0% |